PFE

Pfizer Inc. New York Stock Exchange
$39.38
Open: $38.86 High: $39.45 Low: $38.8 Close: $39.37
Range: 2021-06-19 - 2021-06-21
Volume: 7,741,850
Market: Open
Powered by Finage Stock APIDelayed data
PFE
Pfizer Inc. 235 East 42nd Street New York NY, 10017 http://www.pfizer.com
Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products.
  • CEO: Ian C. Read
  • Employees: 90,200
  • Sector: Healthcare
  • Industry: Drug Manufacturers
PFE News
Latest news about the PFE
  • Canada Easing Border Rules; Indonesia Fights Surge: Virus Update

    (Bloomberg) -- Canada announced a loosening of travel restrictions for fully vaccinated people. South Africa, France and the World Health Organization are set to announce plans for Africa’s first Covid-19 vaccine facility using messenger RNA.U.K. Prime Minister Boris Johnson said England is on track for curbs to be lifted in July, while Germany warned a fourth wave is possible. Hong Kong cut its mandatory hotel quarantine in half for international travelers from most places.Cases surged in Indon

    View More →
  • Pfizer Vaccine Approved for 12-15-Year Olds in New Zealand – Report

    New Zealand has tentatively cleared the COVID-19 vaccine that Pfizer (PFE) developed in partnership with BioNTech (BNTX) for 12-15-year olds, according to a Reuters report. “After careful consideration of the most up-to-date scientific and medical data available, Medsafe has announced provisional approval for our young people to be given the Pfizer vaccine,” Reuters quoted PM Jacinda Ardern as saying. Medsafe is New Zealand’s drugs regulator. The country has more than 250,000 children aged 12 -

    View More →
  • Will Emergence of COVID-19 Delta Variant Aid Vaccine Makers?

    The new variant of COVID-19 virus, delta, is increasing the risk of infections across the globe. This will likely lead to higher demand for COVID-19 vaccines and therapeutics.

    View More →
  • India in talks to find 'middle ground' with Pfizer, others for vaccine imports -govt official

    India's government is in talks with Pfizer and other vaccine manufacturers for import of their COVID-19 vaccines in accordance with local laws, a senior government official said on Monday. Any final decision on vaccine imports has to be compatible with Indian laws and the government was hopeful that these vaccines would be available in the country before the end of this year, Paul said.

    View More →
  • U.S. Warns China on Covid Origin; Cruise Sets Sail: Virus Update

    (Bloomberg) -- China will risk international isolation if it fails to allow a “real” investigation on its territory into the origins of the virus that caused the pandemic, U.S. National Security Adviser Jake Sullivan said. President Joe Biden is traveling to North Carolina on Thursday to encourage more Americans to get vaccinated.Russia, Germany and Portugal reported an expanding spread of the highly transmissible delta variant that first appeared in India. Scott Gottlieb, a former head of the U

    View More →
  • UPDATE 3-Philippines seals biggest COVID-19 vaccine order yet, for 40 mln Pfizer doses

    The Philippine government has signed a supply agreement for 40 million doses of the COVID-19 vaccine developed by Pfizer Inc and BioNTech SE, in its biggest coronavirus vaccine deal to date. Deliveries of the vaccine will begin in late September, Carlito Galvez, head of the government's COVID-19 vaccine procurement, said on Sunday. The Philippines has now ordered 113 million doses from five vaccine manufacturers, including 26 million from China's Sinovac , 10 million of Russia's Sputnik V, 20 million doses from Moderna and 17 million doses from AstraZeneca.

    View More →
  • Swiss to start inoculating youngsters against COVID-19 as early as next week

    Switzerland plans to allow 12- to 15-year olds to receive vaccinations against COVID-19 as soon as next week, government vaccine chief Christoph Berger told Swiss newspaper NZZ in an interview published on Sunday. "Young people who want to be vaccinated should be given the opportunity," Berger told NZZ, adding the government's approval was expected to be communicated next week. "For those with pre-existing conditions or those in contact with immunocompromised individuals who are at risk, vaccination makes sense," he said, adding that - unlike for older populations - it would not be necessary to target a vaccination rate for the 12- to 15-year old population.

    View More →
  • Israel says COVID-19 vaccines rejected by Palestinians were safe

    COVID-19 vaccines delivered by Israel and then rejected by the Palestinian Authority (PA) over their expiration date were fine, the Israeli health ministry said on Saturday. Israel and the PA on Friday announced a vaccine swap deal that would have seen Israel send up to 1.4 million doses of the vaccine made jointly by Pfizer (PFE.N) and BioNTech (22UAy.DE) to the PA in exchange for receiving a reciprocal number of doses later this year. But soon after the announcement, the PA cancelled the deal and said it had sent an initial shipment of around 90,000 doses back to Israel.

    View More →
  • Indonesia to get Pfizer/BioNTech COVID-19 vaccine from August - ministry

    Indonesia will receive 50 million doses of the COVID-19 vaccine jointly made by Pfizer (PFE.N) and BioNTech (22UAy.DE), with the first batch expected in August, a senior health ministry official said on Saturday. "Pfizer vaccines will start arriving from August, with shipments of between 7.5 million to 12 million doses per month,” said Siti Nadia Tarmizi, adding that the supply is the result of a direct government purchase. The Southeast Asia's biggest country is grappling with a fresh increase in coronavirus infections in recent weeks.

    View More →
  • Pfizer's COVID Vaccine Is Even More Amazing Than You Think

    When they did -- thanks to Pfizer, BioNTech, and Moderna -- the results were much better than most had hoped for. The Pfizer-BioNTech drug -- now marketed as Comirnaty -- was the first to share phase 3 data. Moderna followed two weeks later with its own impressive results.

    View More →
  • What to Make of the CDC's Latest Efficacy Data on Pfizer's and Moderna's COVID Vaccines

    It hasn't been a secret that the COVID-19 vaccines developed by Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) are highly effective. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss what investors should make of the latest CDC data.

    View More →
  • Pfizer Announces Ramcess Jean-Louis as Global Chief Diversity, Equity And Inclusion Officer

    Pfizer has recently announced that the company has named Ramcess Jean-Louis, Esq. as Global Chief Diversity, Equity, and Inclusion (DEI) Officer

    View More →
  • Pfizer CEO Urges Biden to Form Bipartisan Coalition on Drug Costs

    Jun.18 -- Pfizer Chairman and CEO Albert Bourla says the out-of-pocket drug costs now paid by U.S. patients “is something that needs to be fixed" and suggests President Joe Biden form a bipartisan coalition in Washington to address the problem. Bourla speaks to Bloomberg's David Westin on "Balance of Power."

    View More →
  • Is Pfizer Stock A Buy As It Eyes $26 Billion In Full-Year Covid Vaccine Sales?

    Pfizer stock briefly broke out in May after the company called for $26 billion in full-year coronavirus vaccine sales. Is PFE stock a buy right now?

    View More →
  • Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal

    AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.

    View More →
  • 12 Words From CureVac's CEO That Could Mean Billions for Moderna and Pfizer

    The European Commission already has signed an advance purchase agreement for as many as 405 million doses from the company. "Demonstrating high efficacy in this unprecedented broad diversity of variants is challenging," CureVac CEO Franz-Werner Haas said when reporting the interim trial analysis.

    View More →
  • Curevac shares climb 10%; CFO says not giving up on COVID-19 vaccine

    Shares of Curevac rose 10% in premarket trading on Friday. Shares of the German biotech have lost 48% this week after the company said a late-stage clinical trial of its COVID-19 vaccine was only 47% effective . But Curevac's chief financial officer, Pierre Kemula, said the company hopes its candidate can still be of use, when a final analysis is done, with that data just two or three weeks away. "We need to look at the data and see, OK, what would be the best value, how we can place this vaccin

    View More →
  • How Does Novavax Stack Up Against Today's Vaccine Leaders?

    Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) have remained a step ahead of most potential coronavirus vaccine rivals. Novavax (NASDAQ: NVAX) plans to submit its coronavirus vaccine candidate for emergency authorization in various countries including the U.S. in the third quarter. Now the question is whether Novavax has what it takes to join leaders Pfizer and Moderna at the top.

    View More →
  • CORRECTED-UPDATE 5-Palestinians cancel deal for near-expired COVID vaccines from Israel

    The Palestinian Authority (PA) cancelled a deal on Friday to receive soon-to-expire COVID-19 vaccines from Israel after an initial Israeli shipment showed an expiration date sooner than had been agreed, the PA health minister said. Israel and the PA announced a vaccine swap deal earlier on Friday that would have seen Israel send up to 1.4 million Pfizer-BioNTech doses to the PA, in exchange for receiving a reciprocal number of doses from the PA later this year.

    View More →
  • UPDATE 1-S.Korea to mix-and-match COVID-19 vaccine doses for 760,000 people

    Some 760,000 South Koreans who have received a first dose of AstraZeneca Plc's COVID-19 vaccine will be offered Pfizer Inc's vaccine as a second shot due to shipment delays by global vaccine sharing scheme COVAX, the government said. Several countries, including Canada and Spain, have already approved such dose-mixing mainly due to concerns about rare and potentially fatal blood clots linked to the AstraZeneca vaccine. A Spanish study found that giving a dose of the Pfizer shot to people who already received the AstraZeneca vaccine is highly safe and effective, according to preliminary results.

    View More →